{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026146","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.989809+00:00","generated_at":"2026-05-15T14:43:54.631708+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates","bullets":["Cash and marketable securities $113.1M; net loss $51M for full year 2025.","Completed Phase 1 PK trial of denifanstat+resmetirom; Phase 2 combo trial in F4 MASH expected 2H 2026.","Exclusive license from TAPI for innovative resmetirom API forms to develop fixed-dose combination.","Ascletis reported positive Phase 3 acne data for denifanstat; NDA accepted by China NMPA.","Initiated Phase 1 trial of TVB-3567, a FASN inhibitor for acne."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026146","json":"https://secwatch.observer/filing/0001104659-26-026146.json","markdown":"https://secwatch.observer/filing/0001104659-26-026146.md","text":"https://secwatch.observer/filing/0001104659-26-026146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/0001104659-26-026146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T14:43:54.631708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74112263470c82e7364cd485d7eaadb29b472dda","claim":"Sagimet Biosciences Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 11, 2026, Sagimet Biosciences Inc. (the \"Company\") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/0001104659-26-026146-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}